Philippe Ronchin

3.9k total citations
36 papers, 469 citations indexed

About

Philippe Ronchin is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Philippe Ronchin has authored 36 papers receiving a total of 469 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 18 papers in Surgery and 15 papers in Oncology. Recurrent topics in Philippe Ronchin's work include Prostate Cancer Treatment and Research (16 papers), Colorectal and Anal Carcinomas (12 papers) and Prostate Cancer Diagnosis and Treatment (10 papers). Philippe Ronchin is often cited by papers focused on Prostate Cancer Treatment and Research (16 papers), Colorectal and Anal Carcinomas (12 papers) and Prostate Cancer Diagnosis and Treatment (10 papers). Philippe Ronchin collaborates with scholars based in France, Belgium and Spain. Philippe Ronchin's co-authors include Frédéric Peyrade, X. Tchiknavorian, Karen Bénézery, Éric François, Naji Salem, Emmanuel Guardiola, D. Azria, Xavier Pivot, L. Chaigneau and Didier Cupissol and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

Philippe Ronchin

28 papers receiving 463 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philippe Ronchin France	12	327	185	182	83	64	36	469
Ali Hasbini France	13	346 1.1×	104 0.6×	137 0.8×	114 1.4×	100 1.6×	47	502
Virag Dandekar United States	4	151 0.5×	168 0.9×	234 1.3×	64 0.8×	113 1.8×	6	527
Ji Hyeon Joo South Korea	13	151 0.5×	142 0.8×	125 0.7×	92 1.1×	37 0.6×	53	463
Manoj Gupta India	12	282 0.9×	127 0.7×	99 0.5×	176 2.1×	14 0.2×	48	514
Cheng‐Hsiang Lo Taiwan	15	173 0.5×	142 0.8×	129 0.7×	96 1.2×	44 0.7×	40	501
Benedetta Agresti Italy	12	166 0.5×	130 0.7×	137 0.8×	108 1.3×	41 0.6×	36	467
Paolo Montemaggi Italy	11	256 0.8×	252 1.4×	202 1.1×	76 0.9×	9 0.1×	37	518
Dori Giroux United States	8	420 1.3×	56 0.3×	171 0.9×	150 1.8×	19 0.3×	9	618
Esra Kaytan Türkiye	10	189 0.6×	174 0.9×	240 1.3×	16 0.2×	116 1.8×	18	480
Yungpo Bernard Su United States	7	263 0.8×	157 0.8×	255 1.4×	34 0.4×	174 2.7×	11	549

Countries citing papers authored by Philippe Ronchin

Since Specialization

Citations

This map shows the geographic impact of Philippe Ronchin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Ronchin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Ronchin more than expected).

Fields of papers citing papers by Philippe Ronchin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Ronchin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Ronchin. The network helps show where Philippe Ronchin may publish in the future.

Co-authorship network of co-authors of Philippe Ronchin

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Ronchin. A scholar is included among the top collaborators of Philippe Ronchin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Ronchin. Philippe Ronchin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roubaud, Guilhem, Marie Kostine, Ray McDermott, et al.. (2025). Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. European Journal of Cancer. 218. 115293–115293. 2 indexed citations

Lemanski, C., P. Pommier, Karine Le Malicot, et al.. (2024). Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE. British Journal of Cancer. 130(5). 769–776. 1 indexed citations

Scoazec, Jean‐Yves, et al.. (2024). 1595MO Phenotypic and genomic characterization of de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase III trial. Annals of Oncology. 35. S962–S962.

François, Éric, Nicolas Magné, Rabia Boulahssass, et al.. (2024). Short course radiotherapy versus radiochemotherapy for locally advanced rectal cancers in the elderly (UNICANCER PRODIGE 42/GERICO 12 study): Quality of life and comprehensive geriatric assessment. Radiotherapy and Oncology. 193. 110144–110144.

Bossi, Alberto, Stéphanie Foulon, Xavier Maldonado, et al.. (2024). Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. The Lancet. 404(10467). 2065–2076. 21 indexed citations

Lemanski, C., P. Pommier, Karine Le Malicot, et al.. (2024). Chemoradiotherapy versus radiotherapy alone in the management of early-stage anal squamous cell carcinoma: A comparative analysis of the French cohort FFCD-ANABASE. Digestive and Liver Disease. 57(1). 97–103.

Vendrely, V., Philippe Ronchin, Mathieu Minsat, et al.. (2023). Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial. Radiotherapy and Oncology. 186. 109742–109742. 4 indexed citations

Guérif, S., Florence Castan, E. Meyer, et al.. (2023). OC-0433 GETUG-AFU 22 phase II randomized trial : final results on clinical outcomes with immediate SRT. Radiotherapy and Oncology. 182. S334–S334. 1 indexed citations

Fizazi, Karim, Joan Carles, Guilhem Roubaud, et al.. (2021). LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1. Annals of Oncology. 32. S1299–S1299. 31 indexed citations

10.

Quéro, L., Emilie Barbier, F. Juguet, et al.. (2021). What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort. Digestive and Liver Disease. 53(6). 776–784. 3 indexed citations

11.

Créhange, G., Aurélie Bertaut, Raíssa Antunes Pereira, et al.. (2021). OC-0336 Dose escalated chemoradiotherapy in esophageal cancer : randomized phase 2/3 CONCORDE trial. Radiotherapy and Oncology. 161. S249–S250.

12.

Blanchard, Pierre, Xavier Artignan, Joan Carles, et al.. (2021). 646TiP A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer. Annals of Oncology. 32. S673–S673.

13.

Latorzeff, I., S. Guérif, S. Mathoulin Pelissier, et al.. (2020). Late toxicity and quality of life from GETUG-AFU 22 study.. Journal of Clinical Oncology. 38(6_suppl). 331–331.

14.

Ortholan, Cécile, M. Resbeut, Jean‐Michel Hannoun‐Lévi, et al.. (2011). Anal Canal Cancer: Management of Inguinal Nodes and Benefit of Prophylactic Inguinal Irradiation (CORS-03 Study). International Journal of Radiation Oncology*Biology*Physics. 82(5). 1988–1995. 61 indexed citations

15.

Hannoun‐Lévi, Jean‐Michel, Cécile Ortholan, M. Resbeut, et al.. (2010). High-Dose Split-Course Radiation Therapy for Anal Cancer: Outcome Analysis Regarding the Boost Strategy (CORS-03 Study). International Journal of Radiation Oncology*Biology*Physics. 80(3). 712–720. 31 indexed citations

16.

Guardiola, Emmanuel, Frédéric Peyrade, L. Chaigneau, et al.. (2004). Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. European Journal of Cancer. 40(14). 2071–2076. 82 indexed citations

17.

Ferrero, Jean-Marc, Cyril Foa, Simon Thézenas, et al.. (2004). A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer. Oncology. 66(4). 281–287. 28 indexed citations

18.

Ferrero, J-M, Cyril Foa, Simon Thézenas, et al.. (2003). A phase II of weekly docetaxel for hormone refractory metastatic prostate cancer (HRMPC). European Urology Supplements. 2(1). 24–24. 1 indexed citations

19.

Sanson, Marc, Alain Améri, A. Monjour, et al.. (1996). Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide: a phase II study. European Journal of Cancer. 32(13). 2229–2235. 37 indexed citations

20.

Baillet, F, et al.. (1996). [Value of the association of partial surgery and postoperative radiotherapy in the management of tumors of the hypopharynx. A study of 141 T1-T2 cases of hypopharyngeal cancer treated by partial surgery, radical surgery or radiotherapy alone].. PubMed. 83(2). 65–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact